Optimizing  ||| S:0 E:11 ||| JJ
use  ||| S:11 E:15 ||| NN
of  ||| S:15 E:18 ||| IN
tumor  ||| S:18 E:24 ||| NN
necrosis  ||| S:24 E:33 ||| NN
factor  ||| S:33 E:40 ||| NN
inhibitors  ||| S:40 E:51 ||| NN
in  ||| S:51 E:54 ||| IN
the  ||| S:54 E:58 ||| DT
management  ||| S:58 E:69 ||| NN
of  ||| S:69 E:72 ||| IN
immune-mediated  ||| S:72 E:88 ||| JJ
inflammatory  ||| S:88 E:101 ||| JJ
diseases  ||| S:101 E:110 ||| NNS
The  ||| S:110 E:114 ||| DT
introduction  ||| S:114 E:127 ||| NN
of  ||| S:127 E:130 ||| IN
anti-tumor  ||| S:130 E:141 ||| JJ
necrosis  ||| S:141 E:150 ||| JJ
factor  ||| S:150 E:157 ||| NN
( ||| S:157 E:158 ||| -LRB-
TNF ||| S:158 E:161 ||| NNP
)  ||| S:161 E:163 ||| -RRB-
therapies  ||| S:163 E:173 ||| NN
has  ||| S:173 E:177 ||| VBZ
dramatically  ||| S:177 E:190 ||| RB
improved  ||| S:190 E:199 ||| VBN
the  ||| S:199 E:203 ||| DT
treatment  ||| S:203 E:213 ||| NN
of  ||| S:213 E:216 ||| IN
immune-mediated  ||| S:216 E:232 ||| JJ
inflammatory  ||| S:232 E:245 ||| JJ
diseases  ||| S:245 E:254 ||| NNS
and  ||| S:254 E:258 ||| CC
provides  ||| S:258 E:267 ||| VBZ
treatment  ||| S:267 E:277 ||| NN
options  ||| S:277 E:285 ||| NNS
for  ||| S:285 E:289 ||| IN
patients  ||| S:289 E:298 ||| NNS
who  ||| S:298 E:302 ||| WP
do  ||| S:302 E:305 ||| VBP
not  ||| S:305 E:309 ||| RB
respond  ||| S:309 E:317 ||| VB
to  ||| S:317 E:320 ||| TO
conventional  ||| S:320 E:333 ||| JJ
disease-modifying  ||| S:333 E:351 ||| JJ
antirheumatic  ||| S:351 E:365 ||| JJ
drugs ||| S:365 E:370 ||| NNS
.  ||| S:370 E:372 ||| .
However ||| S:372 E:379 ||| RB
,  ||| S:379 E:381 ||| ,
the  ||| S:381 E:385 ||| DT
use  ||| S:385 E:389 ||| NN
of  ||| S:389 E:392 ||| IN
anti-TNF  ||| S:392 E:401 ||| JJ
therapies  ||| S:401 E:411 ||| NNS
still  ||| S:411 E:417 ||| RB
needs  ||| S:417 E:423 ||| VBZ
to  ||| S:423 E:426 ||| TO
be  ||| S:426 E:429 ||| VB
optimized ||| S:429 E:438 ||| NNS
.  ||| S:438 E:440 ||| .
Dropoff  ||| S:440 E:448 ||| JJ
rates ||| S:448 E:453 ||| NNS
,  ||| S:453 E:455 ||| ,
patients ||| S:455 E:463 ||| NNS
'  ||| S:463 E:465 ||| POS
lack  ||| S:465 E:470 ||| NN
of  ||| S:470 E:473 ||| IN
response ||| S:473 E:481 ||| NN
,  ||| S:481 E:483 ||| ,
and  ||| S:483 E:487 ||| CC
toxicity  ||| S:487 E:496 ||| NNS
are  ||| S:496 E:500 ||| VBP
issues  ||| S:500 E:507 ||| NNS
that  ||| S:507 E:512 ||| WDT
need  ||| S:512 E:517 ||| VBP
to  ||| S:517 E:520 ||| TO
be  ||| S:520 E:523 ||| VB
addressed  ||| S:523 E:533 ||| VBN
to  ||| S:533 E:536 ||| TO
render  ||| S:536 E:543 ||| VB
these  ||| S:543 E:549 ||| DT
therapies  ||| S:549 E:559 ||| NN
more  ||| S:559 E:564 ||| RBR
effective  ||| S:564 E:574 ||| JJ
for  ||| S:574 E:578 ||| IN
more  ||| S:578 E:583 ||| JJR
patients ||| S:583 E:591 ||| NNS
.  ||| S:591 E:593 ||| .
